[go: up one dir, main page]

AU2018241940B2 - Dihydrotetrabenazine for use in the treatment a movement disorder - Google Patents

Dihydrotetrabenazine for use in the treatment a movement disorder Download PDF

Info

Publication number
AU2018241940B2
AU2018241940B2 AU2018241940A AU2018241940A AU2018241940B2 AU 2018241940 B2 AU2018241940 B2 AU 2018241940B2 AU 2018241940 A AU2018241940 A AU 2018241940A AU 2018241940 A AU2018241940 A AU 2018241940A AU 2018241940 B2 AU2018241940 B2 AU 2018241940B2
Authority
AU
Australia
Prior art keywords
dihydrotetrabenazine
dhtbz
amphetamine
subject
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018241940A
Other languages
English (en)
Other versions
AU2018241940A1 (en
Inventor
Andrew John Duffield
Anant Pandya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adeptio Pharmaceuticals Ltd
Original Assignee
Adeptio Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1705306.7A external-priority patent/GB201705306D0/en
Priority claimed from GBGB1705304.2A external-priority patent/GB201705304D0/en
Priority claimed from GBGB1705305.9A external-priority patent/GB201705305D0/en
Application filed by Adeptio Pharmaceuticals Ltd filed Critical Adeptio Pharmaceuticals Ltd
Publication of AU2018241940A1 publication Critical patent/AU2018241940A1/en
Application granted granted Critical
Publication of AU2018241940B2 publication Critical patent/AU2018241940B2/en
Priority to AU2023274089A priority Critical patent/AU2023274089B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018241940A 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder Active AU2018241940B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023274089A AU2023274089B2 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB1705304.2 2017-04-01
GBGB1705306.7A GB201705306D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GB1705306.7 2017-04-01
GB1705305.9 2017-04-01
GBGB1705304.2A GB201705304D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
GBGB1705305.9A GB201705305D0 (en) 2017-04-01 2017-04-01 Pharmaceutical compositions
US201762515935P 2017-06-06 2017-06-06
US201762515930P 2017-06-06 2017-06-06
US201762515940P 2017-06-06 2017-06-06
US62/515,935 2017-06-06
US62/515,930 2017-06-06
US62/515,940 2017-06-06
PCT/EP2018/058088 WO2018178243A2 (fr) 2017-04-01 2018-03-29 Compositions pharmaceutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023274089A Division AU2023274089B2 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Publications (2)

Publication Number Publication Date
AU2018241940A1 AU2018241940A1 (en) 2019-10-03
AU2018241940B2 true AU2018241940B2 (en) 2023-09-28

Family

ID=63674294

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018241940A Active AU2018241940B2 (en) 2017-04-01 2018-03-29 Dihydrotetrabenazine for use in the treatment a movement disorder
AU2023274089A Active AU2023274089B2 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023274089A Active AU2023274089B2 (en) 2017-04-01 2023-11-28 Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder

Country Status (7)

Country Link
EP (1) EP3606530A2 (fr)
JP (2) JP7250692B2 (fr)
CN (1) CN110691596A (fr)
AU (2) AU2018241940B2 (fr)
CA (1) CA3057548A1 (fr)
RU (2) RU2022104034A (fr)
WO (1) WO2018178243A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
WO2019241555A1 (fr) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Composés inhibiteurs de vmat2, compositions et méthodes associées
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2022081532A1 (fr) * 2020-10-12 2022-04-21 Auspex Pharmaceuticals, Inc. Formes galéniques à rétention gastrique comprenant de la deutétrabénazine
CN119894884A (zh) * 2022-09-08 2025-04-25 莱德克斯制药有限公司 Rock抑制剂的固体形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120110A2 (fr) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Nouvelles formulations pharmaceutiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH341161A (de) * 1956-02-08 1959-09-30 Hoffmann La Roche Verfahren zur Herstellung von substituierten 2-Hydroxy-benzo [ a ] chinolizinen
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (fr) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Traitement de l'hypercinesie associant l'amantadine a un compose tetrabenazinique
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
AU2007317242B2 (en) * 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011153157A2 (fr) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Inhibiteurs benzoquinolone de vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
KR20220140647A (ko) * 2014-05-06 2022-10-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120110A2 (fr) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Nouvelles formulations pharmaceutiques

Also Published As

Publication number Publication date
JP7595630B2 (ja) 2024-12-06
WO2018178243A3 (fr) 2018-12-13
RU2022104034A (ru) 2022-03-05
CA3057548A1 (fr) 2018-10-04
RU2019134416A3 (fr) 2021-08-18
AU2018241940A1 (en) 2019-10-03
JP2023029975A (ja) 2023-03-07
CN110691596A (zh) 2020-01-14
WO2018178243A2 (fr) 2018-10-04
AU2023274089B2 (en) 2025-04-10
EP3606530A2 (fr) 2020-02-12
AU2023274089A1 (en) 2023-12-14
JP7250692B2 (ja) 2023-04-03
RU2019134416A (ru) 2021-05-04
RU2768738C2 (ru) 2022-03-24
JP2020512987A (ja) 2020-04-30

Similar Documents

Publication Publication Date Title
AU2023274089B2 (en) Dihydrotetrabenazine For Use In The Treatment of a Movement Disorder
AU2023274090B2 (en) (+)-Alpha-Dihydrotetrabenazine for use in the Treatment of a Movement Disorder
US11844786B2 (en) Uses of combinations (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in methods of treating movement disorder
US11844794B2 (en) Pharmaceutical compositions
US20220211678A1 (en) Uses of (+)-a-dihydrotetrabenazine in methods of treating movement disorder
US20180280360A1 (en) Pharmaceutical compositions
US10668052B2 (en) Combinations of isomers of dihydrotetrabenazine
EP3860599B1 (fr) Régime posologique de (+)-alpha-dihydrotétrabénazine destiné au traitement de troubles du mouvement
RU2783865C2 (ru) Фармацевтические композиции
AU2019273656A1 (en) Pharmaceutical compounds for use in treating Huntington's disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)